
Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.

Prof. Claus Bachert describes how type 2 inflammation drives CRSwNP.

Join Dr. Celeste Porsbjerg as she discussed on how type 2 inflammation may lead to airway remodeling in asthma, exploring the pathophysiologic mechanisms, that ultimately lead to structural changes and irreversible loss of lung function

Join Dr. Celeste Porsbjerg as she explores the mechanisms underlying mucus plugging development as mucociliary clearance. She explains how type 2 cytokines—particularly IL-13—impair this clearance mechanism, leading to mucus plugging, and worsened asthma outcomes.

Dr Hawkes provides an overview of the distinctive characteristics of wheals and angioedema in clinical manifestation

Dr. Hawkes highlights how Chronic Urticaria is a mast cell centric disease with moderate levels of spontaneous remission in patients.
Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Brian Kim explores the histaminergic and nonhistaminergic mechanisms of itch, highlighting how type 2 cytokines like IL-4 serve as central orchestrators of neuronal sensitization and immune–nervous system cross-talk.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Brian Kim describes the dynamic neuroimmune interactions in chronic pruritic skin diseases, emphasizing how type 2 cytokines and sensory nerves actively influence both itch perception and tissue inflammation.

In this exclusive video interview, Dr Amy Paller discusses two topics: 1) The importance of CCL17 (TARC) as a biomarker in pediatric patients with AD, and 2) How IL-4 and IL-13 contribute to skin barrier dysfunction in AD.

Understand the drivers of lung function decline in chronic obstructive pulmonary disease (COPD), including chronic inflammation, key risk factors, and the impact on patient well-being .

Dr. Simpson explores the concept of remission in AD, focusing on minimal disease activity and long-term remission, discussing how disease modification in AD can impact the course of the disease and its associated comorbidities.